Articles

Find an Article

Filter articles

Applied Filters

Showing 71 to 80 of 136 results

Further unravelling the SPC Gordian Knot

EU01-10-2015Avi Toltzis and Penny Gilbert

The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain.

SPCs: Questions of validity

Austria, EU01-10-2015Michael Pitzner-Bruun

The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports.

SPCs: When a few days makes a difference

EU01-10-2015Anja Lunze and Paul England

An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing.

Warner-Lambert v Actavis: lessons from ‘the case of the year’

UK01-10-2015Arty Rajendra

The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal.

SPCs: When a few days makes a difference

Austria, EU24-09-2015Anja Lunze and Paul England

An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing.

London calling: the benefits of the UPC’s new home

UK10-09-2015Claire Phipps-Jones

Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows.

From profits to damages: Canada’s NIA defence

Canada20-08-2015Mark Biernacki and Cameron Weir

A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies.

Patent portfolios: maximise the value and minimise the cost

UK06-08-2015Bruno Reynolds

Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more.

Will you, won’t you, will you join the dance?

US30-07-2015Courtenay Brinckerhoff

On July 21 the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz that biosimilar applicants can opt out of the ‘patent dance’. Courtenay Brinckerhoff of Foley & Lardner considers the decision’s implications for the biosimilars framework and highlights the questions that remain unanswered.

The devil in the judicial detail

International25-06-2015Paul England

The judiciary system for the new Unified Patent Court has been the subject of much discussion. As part of a regular column, Paul England, senior associate at law firm Taylor Wessing and who chaired a recent discussion between a panel of experts, examines the issue.

Showing 71 to 80 of 136 results

LSIPR